NASDAQ: DAVIDavion Healthcare PLC Stock
$6.00-5.65 (-48.5%)
Updated Oct 23, 2026
DAVI Price
$6.00
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$5.67
52 Week High
$12.30
P/E
-171.43x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$968.25k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$379
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DAVI Overview
Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers. Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result. It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. Davion operates a licensing model and has a global manufacturing and distribution agreement for BreastCheck with NeuRX Health Inc., which provides $120 million in staged license fees and minimum annual royalties of $10 million over an initial ten-year term. The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary. It plans to pair product commercialization with acquisitions of complementary healthcare businesses, and has launched a £30 million five-year senior secured bond through Davion Healthcare Finance Ltd. The listing is a direct listing of 25,000,000 existing ordinary shares, with no new capital raised.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DAVI's potential to beat the market
- DAVI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
DAVI
RankedUnranked of 39
RankedUnranked of 39
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $118.51 | A | |
| $166.62 | A | |
| $13.94 | A |
Be the first to know about important DAVI news, forecast changes, insider trades & much more!
DAVI News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DAVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DAVI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DAVI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
DAVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more DAVI due diligence checks available for Premium users.
Valuation
DAVI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-171.43x
Industry
47.92x
Market
46.1x
DAVI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
DAVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$76.5M
Liabilities
$1.2M
Debt to equity
0.02
DAVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
DAVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Davion Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.